News

The letter clearly states that the FDA currently has no plans to convene an advisory committee meeting. This development marks an important step forward for Savara in the regulatory approval process. Typically, the FDA conducts in-depth evaluations of innovative therapies through advisory committee meetings, and the decision not to hold such a meeting this time may indicate an accelerated approval process. The company stated that it will continue to maintain close communication with the FDA and actively advance the review of the relevant drug. The market is watching to see whether this move means Savara's R&D project will receive faster regulatory feedback.

According to the cryptocurrency position weekly report released by CME, BTC positions stand at 20,302 contracts, a decrease of 11.41% compared to the previous week; ETH positions are at 34,357 contracts, a decrease of 7.36% week-on-week.

The S&P 500 index preliminarily closed down 1.3%, with the materials sector falling 2%, and the consumer discretionary, technology, financial, industrial, telecommunications, and real estate sectors each dropping up to 1.9%. The Nasdaq 100 index preliminarily closed down 1.5%. Among its constituents, ODFL preliminarily closed down 7.7%, Lam Research fell 7.3%, Micron Technology, Applied Materials, KLA, ASML ADR, Intel, and Arm Holdings each dropped up to 6.7%. Palantir and Intuit rose 3%, while Marvell Technology surged 18%. Caterpillar preliminarily closed down 3.4%, Nvidia fell 3.1%, Amazon, American Express, and 3M each dropped over 2%, leading the declines among Dow Jones components. Salesforce rose 0.1%, IBM gained 0.5%, and Boeing climbed 3.9%.